کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3337109 1591050 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern
ترجمه فارسی عنوان
ارزش پیش بینانه نشانگرهای تومور در بیماران مبتلا به سرطان کبد مجاری ادراری در الگوی مختلف تهاجم عروقی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کبدشناسی
چکیده انگلیسی

BackgroundFour tumor markers for hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), glypican-3 (GPC3), vascular endothelial growth factor (VEGF) and des-gamma-carboxy prothrombin (DCP), are closely associated with tumor invasion and patient's survival. This study estimated the predictability of preoperative tumor marker levels along with pathological parameters on HCC recurrence after hepatectomy.MethodsA total of 140 patients with HCC who underwent hepatectomy between January 2012 and August 2012 were enrolled. The demographics, clinical and follow-up data were collected and analyzed. The patients were divided into two groups: patients with macroscopic vascular invasion (MaVI+) and those without MaVl (MaVI-). The predictive value of tumor markers and clinical parameters were evaluated by univariate and multivariate analysis.ResultsIn all patients, tumor size (>8 cm) and MaVI were closely related to HCC recurrence after hepatectomy. For MaVI+ patients, VEGF (>900 pg/mL) was a significant predictor for recurrence (RR=2.421; 95% CI: 1.272–4.606; P=0.007). The 1- and 2-year tumor-free survival rates for MaVI+ patients with VEGF ≤900 pg/mL versus for those with VEGF >900 pg/mL were 51.5% and 17.6% versus 19.0% and 4.8% (P>0.001). For MaVI-patients, DCP >445 mAu/mL and tumor size >8 cm were two independent risk factors for tumor recurrence (RR=2.307, 95% CI: 1.132–4.703, P=0.021; RR=3.150, 95% CI: 1.392–7.127, P=0.006; respectively). The 1- and 2-year tumor-free survival rates for the patients with DCP ≤445 mAu/mL and those with DCP >445 mAu/mL were 90.4% and 70.7% versus 73.2% and 50.5% respectively (P=0.048). The 1- and 2-year tumor-free survival rates for the patients with tumor size ≤8 cm and >8 cm were 83.2% and 62.1% versus 50.0% and 30.0%, respectively (P=0.003).ConclusionsThe MaVI+ patients with VEGF ≤900 pg/mL had a relatively high tumor-free survival than those with VEGF >900 pg/mL, In the MaVI-patients, DCP >445 mAu/mL and tumor size >8 cm were predictive factors for postoperative recurrence.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Hepatobiliary & Pancreatic Diseases International - Volume 15, Issue 4, 15 August 2016, Pages 371–377
نویسندگان
, , , , , , , , , ,